Inferra AIResearch Tools

Inferra AI / Company / KURA

Kura Oncology, Inc.

KURA · Health Care

Last earnings Aug 12, 2026

Key results

Collaboration revenuequarter

$15.3 million

Financial Results • Collaboration revenue from our Kyowa Kirin partnership for the second quarter of 2025 was $15.3 million, compared to no revenue for the second quarter of 2024.

SEC original ↗Kura Oncology, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025

AI analysis

Q2 2025 · reported Aug 7, 2025

Based on: Earnings release + parent 8-K — transcript not held

Collaboration revenue · Q2 2025
$15.3M
EX-99 · Aug 7, 2025

Headline figures

MetricQ2 2025Prior qtrYear ago
Collaboration revenue$15.3 million——

EX-99 · Aug 7, 2025

Guidance · company-stated

No guidance located in the held release

Next earningsNo verified date on fileNo date is estimated or imported
General educational research only — not investment advice.Every figure is as stated in the held documents; values marked “computed from stated figures” are arithmetic on those stated figures. Guidance shown is the company’s own stated guidance. No price targets, no recommendations, no consensus estimates.

Event summary

(Kyowa Kirin) announced the U.S

Based on: Earnings release + parent 8-K — transcript not held

Guidance & outlook

No guidance located in the held release

Strategy & priorities

” Recent Highlights • FDA Priority Review of New Drug Application for ziftomenib with PDUFA target action date of November 30, 2025 – In June 2025, Kura and Kyowa Kirin Co.

SEC original ↗Kura Oncology, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025

The application has been granted Priority Review and assigned a PDUFA target action date of November 30, 2025 .

SEC original ↗Kura Oncology, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025

• Presentation of clinical data from the Phase 1b expansion cohort of KOMET-007 evaluating ziftomenib in combination with intensive chemotherapy (7+3) in newly diagnosed NPM1 -m and KMT2A -rearranged AML at 2025 EHA Congress – High rates of CR and measurable residual disease (MRD) negativity with ziftomenib in combination with intensive chemotherapy in newly diagnosed NPM1-m and KMT2A-rearranged (KMT2A-r) AML were reported.

SEC original ↗Kura Oncology, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025

• Present preliminary clinical data from the KOMET-007 Phase 1b expansion cohort evaluating ziftomenib in combination with venetoclax and azacitidine in the second half of 2025.

SEC original ↗Kura Oncology, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025

• Initiate one or more FIT-001 expansion cohorts of KO-2806 and cabozantinib in patients with advanced renal cell carcinoma in the second half of 2025.

SEC original ↗Kura Oncology, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025

Risks & headwinds

Forward-Looking Statements This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements.

SEC original ↗Kura Oncology, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025

For a further list and description of the risks and uncertainties the Company faces, please refer to the Company's periodic and other filings with the Securities and Exchange Commission, which are available at www.

SEC original ↗Kura Oncology, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025

Competitors

Competitors & peers

Same GICS sector — classification peers, not declared competitors

Gilead Sciences (GILD) Health CareGenmab (GMAB) Health CareAlcon (ALC) Health CareArgenx (ARGX) Health CareSanofi (SNY) Health CareMerck & Co. (MRK) Health CareXencor Inc (XNCR) Health CareIllumina, Inc. (ILMN) Health Care
Documents

Filings

33 documents

Earnings releases

9 documents

Presentations

0 documents

No presentations for Kura Oncology, Inc. are held in this edition of the library.

Transcripts

0 documents

No transcripts for Kura Oncology, Inc. are held in this edition of the library.

See also the earnings calendar for every tracked company’s next earnings date.